Supernus Pharmaceuticals Revenue 2011-2024 | SUPN

Supernus Pharmaceuticals revenue from 2011 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Supernus Pharmaceuticals Annual Revenue
(Millions of US $)
2023 $608
2022 $667
2021 $580
2020 $520
2019 $393
2018 $409
2017 $302
2016 $215
2015 $147
2014 $93
2013 $12
2012 $1
2011 $1
2010 $0
Supernus Pharmaceuticals Quarterly Revenue
(Millions of US $)
2024-06-30 $168
2024-03-31 $144
2023-12-31 $164
2023-09-30 $154
2023-06-30 $136
2023-03-31 $154
2022-12-31 $167
2022-09-30 $177
2022-06-30 $170
2022-03-31 $153
2021-12-31 $159
2021-09-30 $148
2021-06-30 $141
2021-03-31 $131
2020-12-31 $144
2020-09-30 $155
2020-06-30 $127
2020-03-31 $95
2019-12-31 $100
2019-09-30 $102
2019-06-30 $105
2019-03-31 $85
2018-12-31 $116
2018-09-30 $103
2018-06-30 $100
2018-03-31 $90
2017-12-31 $88
2017-09-30 $80
2017-06-30 $76
2017-03-31 $58
2016-12-31 $62
2016-09-30 $57
2016-06-30 $52
2016-03-31 $44
2015-12-31 $44
2015-09-30 $39
2015-06-30 $36
2015-03-31 $29
2014-12-31 $31
2014-09-30 $23
2014-06-30 $30
2014-03-31 $9
2013-12-31 $10
2013-09-30 $1
2013-06-30 $0
2013-03-31 $0
2012-12-31 $1
2012-09-30 $0
2012-06-30 $0
2012-03-31 $0
2011-12-31 $0
2011-09-30 $0
2011-06-30 $1
2011-03-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.872B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00